This study examined the treatment and outcomes of 162 patients diagnosed with hemophagocytic lymphohistiocytosis (HLH) across four medical centers. The first-line treatments primarily involved anti-infective therapy and symptomatic management, while some patients received combined therapy regimens that included chemotherapy with gamma globulin or glucocorticoids with gamma globulin. The main goal was to see how these different approaches affected survival rates.
The results showed that 90 of the 162 patients survived, while 72 died. Researchers identified several factors linked to survival, including tumor history, ferritin levels, and how quickly treatment began. Specifically, combined therapy regimens appeared to offer better clinical efficacy and survival benefits compared to monotherapy in certain groups.
No safety concerns or adverse events were reported in this review of past records. However, because the study looked backward at existing data, it cannot prove that the treatments caused the survival benefits. Readers should understand that these findings highlight the need for treatment strategies tailored to the specific cause of HLH, but they do not replace current clinical guidelines.